Samsung BioLogics (KOSPI:KRX: 207940)

4:00 PM - 4:15 PM, Wednesday, June 5, 2019 ・ Theater 1
Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung has a long, rich history of research and development work. Our biologics business builds on principles of our past achievements and brings our technological leadership to the biologics sector. With Samsung’s quality, technology and innovation, Samsung BioLogics will establish a new global standard for best practices within biopharmaceutical manufacturing and transform global healthcare as we know it. We are committed to excellence in the development and manufacturing of bio-healthcare products. Our client-oriented business model encourages high-standard, fast-turnaround contract manufacturing partnerships. Furthermore, our state-of-the-art facilities are fully compliant with global healthcare regulations and cGMP standards. To better serve the patients of our partners, we provide the proper infrastructure to develop, refine, and distribute biopharmaceutical products worldwide.
Ticker:
KRX: 207940
Exchange:
KOSPI
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
CMO
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Business Development Lead
Samsung BioLogics